274 related articles for article (PubMed ID: 14712441)
1. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
Desnick RJ; Banikazemi M; Wasserstein M
Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
[TBL] [Abstract][Full Text] [Related]
3. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
4. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P
Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006
[TBL] [Abstract][Full Text] [Related]
5. Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys.
Cybulla M; Schaefer E; Wendt S; Ling H; Kröber SM; Hövelborn U; Schandelmaier S; Rohrbach R; Neumann HP
Am J Kidney Dis; 2005 May; 45(5):e82-9. PubMed ID: 15861341
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
7. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
8. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
10. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease: renal biopsy-proven cases from China.
Zhang SH; Liu ZH; Zeng CH; Li SJ; Chen HP; Su J; Li LS
J Nephrol; 2007; 20(6):716-26. PubMed ID: 18046674
[TBL] [Abstract][Full Text] [Related]
12. First phenotypic description of a female patient with c.610 T > C variant of GLA: a renal-predominant presentation of Fabry disease.
Greillier S; Daniel L; Caillaud C; Dussol B; Touchard G; Goujon JM; Jourde-Chiche N; Bobot M
BMC Med Genet; 2020 Jun; 21(1):137. PubMed ID: 32590976
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes.
Glass RB; Astrin KH; Norton KI; Parsons R; Eng CM; Banikazemi M; Desnick RJ
J Comput Assist Tomogr; 2004; 28(2):158-68. PubMed ID: 15091117
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease. A case report.
Kotnik J; Kotnik F; Desnick RJ
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Mar; 14(1):15-9. PubMed ID: 15818441
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: cardiac manifestations and therapeutic options.
Pierre-Louis B; Kumar A; Frishman WH
Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
[TBL] [Abstract][Full Text] [Related]
17. Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype-phenotype expression.
Paliouras C; Aperis G; Lamprianou F; Ntetskas G; Roufas K; Alivanis P
Nefrologia; 2015; 35(6):578-81. PubMed ID: 26384850
[TBL] [Abstract][Full Text] [Related]
18. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
19. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
20. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]